search

Active clinical trials for "Syndrome"

Results 4381-4390 of 9759

XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

Restless Legs Syndrome

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

Completed6 enrollment criteria

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

Restless Legs Syndrome

The primary objective of this study is to assess the safety and tolerability of ropinirole XR in the long-term treatment (up to 52 weeks)of adults with RLS.

Completed26 enrollment criteria

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated...

Restless Legs SyndromeDepression

The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment

Completed29 enrollment criteria

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Metabolic SyndromeInsulin Resistance

The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.

Completed2 enrollment criteria

Safety and Pharmacokinetic Study of BIO 300 Capsules

Acute Radiation Syndrome

This trial is designed to evaluate the safety and pharmacokinetics of BIO 300 capsules when administered orally to healthy male and female volunteers. BIO 300 is expected to be safe for use starting at 500 mg.

Completed18 enrollment criteria

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

AIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS Lymphoma54 more

This phase I trial is studying the side effects and best dose of EMD 121974 in treating patients with solid tumors or lymphoma. Cilengitide (EMD 121974) may stop the growth of cancer cells by stopping blood flow to the cancer

Completed35 enrollment criteria

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome,...

NarcolepsySleep Apnea3 more

The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure [nCPAP] therapy), or chronic shift work sleep disorder (SWSD).

Completed27 enrollment criteria

Nursing Management of Irritable Bowel Syndrome:Improving Outcomes

Irritable Bowel Syndrome

The purpose of this study is 1) to determine whether a comprehensive self-management intervention is effective in a sample that includes men and women with irritable bowel syndrome, and 2) to determine whether the comprehensive self-management intervention is as effective when delivered over the telephone as compared to a face-to-face approach.

Completed3 enrollment criteria

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients...

LeukemiaLymphoma3 more

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining total-body irradiation with fludarabine and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.

Completed61 enrollment criteria

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic...

LeukemiaMyelodysplastic Syndromes1 more

RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.

Completed35 enrollment criteria
1...438439440...976

Need Help? Contact our team!


We'll reach out to this number within 24 hrs